Guardant Health announced that the U.S. Food and Drug Administration approved its Guardant360® CDx as a companion diagnostic for BRAFTOVI® (encorafenib) in combination with cetuximab and chemotherapy for patients with BRAF V600E‑mutant metastatic colorectal cancer. The approval, granted on January 22, 2026, expands Guardant’s portfolio into a high‑margin, high‑volume oncology indication that already enjoys a robust reimbursement framework covering more than 300 million U.S. lives.
Guardant’s recent financial results underscore the significance of the approval. In the fourth quarter of 2025, the company reported total revenue of $280 million, up 39% year‑over‑year, and a full‑year 2025 revenue of $981 million, a 33% increase from 2024. Gross margin improved to 66% in Q3 2025 from 63% a year earlier, reflecting stronger mix and pricing power in its core oncology and screening segments. Although Guardant remains unprofitable, free cash‑flow burn narrowed to $54 million in Q4 2025 from $233 million for the full year, and the company’s cash position stood at $1.3 billion.
The FDA approval is expected to accelerate adoption of Guardant360 in oncology practices and add a new revenue stream that aligns with the company’s high‑margin strategy. The BRAF V600E‑mutant metastatic colorectal cancer market is sizable, and the approval positions Guardant to capture a share of the growing companion‑diagnostic market. Management anticipates that the new indication will reinforce Guardant’s competitive moat and contribute to the company’s upward revenue guidance, which was raised to $965–$970 million for full‑year 2025.
Analysts have responded positively to the approval. Stifel lifted its price target to $120, Jefferies to $130, and BTIG named Guardant a top pick for 2026, citing the Shield CRC and G360 tissue launches as key catalysts. The market reaction reflects confidence in Guardant’s ability to translate regulatory approvals into commercial success.
Helmy Eltoukhy, Guardant’s chairman and co‑CEO, said the approval “reinforces our leadership in liquid biopsy and precision oncology, and it will accelerate the adoption of Guardant360 in high‑volume oncology indications.” He added that the company’s “breakout year” in 2025 was driven by “pioneering innovation from our Smart Platform and best‑in‑class commercial execution.”
Guardant faces competition from other diagnostic companies offering liquid biopsy and comprehensive genomic profiling tests, but its first FDA‑approved liquid biopsy for comprehensive genomic profiling gives it a distinct advantage. Strategic partnerships, such as the collaboration with COTA Inc., further strengthen Guardant’s real‑world data and AI analytics capabilities, positioning the company to capitalize on the expanding oncology companion‑diagnostic market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.